Michael Makris/LinkedIn
Mar 2, 2026, 13:42
Michael Makris: How Early Can Hemlibra Be Started?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Eman Hassan et al, published in RPTH Journal:
”How early can you start Hemlibra (emicizumab)?
A paper in the RPTH Journal describes its effective use when started at 26 hours of age, in a baby with hemophilia born 10 weeks premature (at 30 weeks of gestation).”
Title: Emicizumab Prophylaxis in a Preterm Infant with Severe Haemophilia A: A Case Report on the Feasibility of Early Use
Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani
Read the Full Article on RPTH Journal․
Other articles featuring Michael Makris on Hemostasis Today.
-
Apr 16, 2026, 18:27Are We Underestimating VTE After PanNET Surgery? – RPTH Journal
-
Apr 16, 2026, 16:10Hamid Noori: Etiological Classification of Anemia Understanding the Root Cause
-
Apr 16, 2026, 15:29Sebastian Klapa: Key Findings On Mortality And Cardiovascular Risk In ANCA-Associated Vasculitis
-
Apr 16, 2026, 15:23Ifeanyichukwu Ifechidere: Argatroban – Its ‘Rescue Mission’ in Heparin-Induced Thrombocytopenia
-
Apr 16, 2026, 14:58Early Diagnosis Can Change Everything in Hemophilia Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper